Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 234

1.

Gastrointestinal stromal tumour.

Rubin BP, Heinrich MC, Corless CL.

Lancet. 2007 May 19;369(9574):1731-41. Review. Erratum in: Lancet. 2007 Aug 4;370(9585):388.

PMID:
17512858
[PubMed - indexed for MEDLINE]
2.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

PMID:
16638875
[PubMed - indexed for MEDLINE]
Free Article
3.

Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?

Nilsson B, Nilsson O, Ahlman H.

Expert Opin Investig Drugs. 2009 Apr;18(4):457-68. doi: 10.1517/13543780902806400 . Review.

PMID:
19335275
[PubMed - indexed for MEDLINE]
4.

Gastrointestinal stromal tumors: imatinib and beyond.

Schnadig ID, Blanke CD.

Curr Treat Options Oncol. 2006 Nov;7(6):427-37. Review.

PMID:
17032555
[PubMed - indexed for MEDLINE]
5.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
[PubMed - indexed for MEDLINE]
6.

Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.

Sevinc A.

Chemotherapy. 2009;55(2):132-6. doi: 10.1159/000198699. Epub 2009 Feb 3.

PMID:
19188713
[PubMed - indexed for MEDLINE]
7.

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.

Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.

J Clin Oncol. 2009 Jan 20;27(3):439-45. doi: 10.1200/JCO.2008.17.2742. Epub 2008 Dec 8.

PMID:
19064982
[PubMed - indexed for MEDLINE]
8.

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21.

PMID:
19164557
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

KIT mutations in GIST.

Fletcher JA, Rubin BP.

Curr Opin Genet Dev. 2007 Feb;17(1):3-7. Epub 2007 Jan 8. Review.

PMID:
17208434
[PubMed - indexed for MEDLINE]
10.

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.

Pediatr Blood Cancer. 2009 Jul;52(7):767-71. doi: 10.1002/pbc.21909.

PMID:
19326424
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
[PubMed - indexed for MEDLINE]
12.

Novel approaches to imatinib- and sunitinib-resistant GIST.

Reichardt P.

Curr Oncol Rep. 2008 Jul;10(4):344-9. Review.

PMID:
18778561
[PubMed - indexed for MEDLINE]
13.

Developments in targeted therapy of advanced gastrointestinal stromal tumors.

Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA.

Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99. Review.

PMID:
18537751
[PubMed - indexed for MEDLINE]
14.

C-kit, GIST, and imatinib.

Siehl J, Thiel E.

Recent Results Cancer Res. 2007;176:145-51. Review.

PMID:
17607922
[PubMed - indexed for MEDLINE]
15.

Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.

Apice G, Milano A, Bruni GS, Iaffaioli RV, Caponigro F.

Rev Recent Clin Trials. 2006 Jan;1(1):35-42. Review.

PMID:
18393778
[PubMed - indexed for MEDLINE]
16.

Sunitinib for imatinib-resistant GIST.

Joensuu H.

Lancet. 2006 Oct 14;368(9544):1303-4. No abstract available.

PMID:
17046443
[PubMed - indexed for MEDLINE]
17.

Emerging drugs for the treatment of soft tissue sarcomas.

Cassier PA, Dufresne A, Fayette J, Alberti L, Ranchere D, Ray-Coquard I, Blay JY.

Expert Opin Emerg Drugs. 2007 Mar;12(1):139-53. Review.

PMID:
17355219
[PubMed - indexed for MEDLINE]
18.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA.

J Pathol. 2008 Sep;216(1):64-74. doi: 10.1002/path.2382.

PMID:
18623623
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

New paradigms in gastrointestinal stromal tumour management.

Blay JY.

Ann Oncol. 2009 May;20 Suppl 1:i18-24. doi: 10.1093/annonc/mdp075.

PMID:
19430004
[PubMed - indexed for MEDLINE]
Free Article
20.

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.

Reichardt P.

Oncology. 2010;78(2):130-40. doi: 10.1159/000312655. Epub 2010 Apr 13. Review.

PMID:
20389135
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk